Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | NUVB |
---|---|---|
09:32 ET | 21669 | 2.94 |
09:34 ET | 12158 | 2.93 |
09:36 ET | 1600 | 2.915 |
09:38 ET | 14259 | 2.885 |
09:39 ET | 4507 | 2.875 |
09:41 ET | 4179 | 2.875 |
09:43 ET | 1100 | 2.875 |
09:45 ET | 8341 | 2.895 |
09:48 ET | 1543 | 2.885 |
09:50 ET | 1580 | 2.89 |
09:52 ET | 400 | 2.885 |
09:54 ET | 2712 | 2.89 |
09:56 ET | 6375 | 2.875 |
09:57 ET | 2326 | 2.88 |
09:59 ET | 600 | 2.885 |
10:01 ET | 1492 | 2.875 |
10:03 ET | 11144 | 2.87 |
10:06 ET | 10860 | 2.895 |
10:08 ET | 600 | 2.9 |
10:10 ET | 1497 | 2.905 |
10:12 ET | 4895 | 2.89 |
10:14 ET | 210 | 2.9 |
10:15 ET | 100 | 2.8953 |
10:17 ET | 4500 | 2.9 |
10:19 ET | 4009 | 2.9093 |
10:21 ET | 1000 | 2.91 |
10:24 ET | 2600 | 2.905 |
10:26 ET | 100 | 2.91 |
10:28 ET | 2092 | 2.92 |
10:30 ET | 4400 | 2.915 |
10:32 ET | 600 | 2.91 |
10:33 ET | 2600 | 2.9151 |
10:35 ET | 10011 | 2.91 |
10:37 ET | 2999 | 2.905 |
10:39 ET | 3120 | 2.91 |
10:42 ET | 412 | 2.915 |
10:44 ET | 4251 | 2.92 |
10:46 ET | 519 | 2.915 |
10:48 ET | 4260 | 2.935 |
10:50 ET | 800 | 2.94 |
10:51 ET | 8185 | 2.925 |
10:53 ET | 316 | 2.93 |
10:55 ET | 2492 | 2.93 |
10:57 ET | 600 | 2.93 |
11:00 ET | 492 | 2.93 |
11:02 ET | 2187 | 2.915 |
11:04 ET | 600 | 2.92 |
11:06 ET | 5747 | 2.92 |
11:08 ET | 400 | 2.92 |
11:09 ET | 1606 | 2.93 |
11:11 ET | 1408 | 2.925 |
11:13 ET | 4001 | 2.92 |
11:15 ET | 100 | 2.915 |
11:18 ET | 100 | 2.915 |
11:20 ET | 200 | 2.92 |
11:22 ET | 300 | 2.915 |
11:24 ET | 100 | 2.92 |
11:26 ET | 4400 | 2.9199 |
11:27 ET | 4665 | 2.925 |
11:29 ET | 300 | 2.925 |
11:31 ET | 2231 | 2.92 |
11:33 ET | 596 | 2.92 |
11:36 ET | 200 | 2.92 |
11:38 ET | 200 | 2.925 |
11:40 ET | 11099 | 2.94 |
11:42 ET | 1100 | 2.94 |
11:44 ET | 2902 | 2.95 |
11:45 ET | 2584 | 2.955 |
11:47 ET | 500 | 2.96 |
11:49 ET | 10843 | 2.96 |
11:51 ET | 500 | 2.96 |
11:54 ET | 700 | 2.96 |
11:56 ET | 200 | 2.96 |
11:58 ET | 4621 | 2.955 |
12:00 ET | 596 | 2.955 |
12:02 ET | 3133 | 2.945 |
12:07 ET | 300 | 2.945 |
12:09 ET | 616 | 2.945 |
12:12 ET | 300 | 2.95 |
12:16 ET | 200 | 2.95 |
12:18 ET | 100 | 2.95 |
12:20 ET | 100 | 2.945 |
12:21 ET | 300 | 2.945 |
12:23 ET | 8161 | 2.95 |
12:27 ET | 100 | 2.95 |
12:30 ET | 1712 | 2.95 |
12:32 ET | 1635 | 2.945 |
12:34 ET | 900 | 2.945 |
12:36 ET | 7596 | 2.925 |
12:38 ET | 1100 | 2.925 |
12:39 ET | 1400 | 2.925 |
12:41 ET | 1317 | 2.925 |
12:43 ET | 3149 | 2.915 |
12:45 ET | 700 | 2.915 |
12:48 ET | 2733 | 2.905 |
12:50 ET | 2275 | 2.905 |
12:52 ET | 3000 | 2.9 |
12:54 ET | 900 | 2.9 |
12:56 ET | 8406 | 2.92 |
12:57 ET | 6444 | 2.91 |
12:59 ET | 600 | 2.91 |
01:01 ET | 1246 | 2.905 |
01:06 ET | 1906 | 2.915 |
01:08 ET | 100 | 2.92 |
01:10 ET | 100 | 2.915 |
01:12 ET | 2139 | 2.915 |
01:14 ET | 100 | 2.915 |
01:15 ET | 665 | 2.92 |
01:19 ET | 100 | 2.92 |
01:21 ET | 200 | 2.92 |
01:24 ET | 850 | 2.91 |
01:26 ET | 4044 | 2.915 |
01:28 ET | 100 | 2.915 |
01:30 ET | 548 | 2.92 |
01:32 ET | 356 | 2.915 |
01:33 ET | 400 | 2.92 |
01:35 ET | 423 | 2.9101 |
01:37 ET | 348 | 2.92 |
01:39 ET | 100 | 2.92 |
01:42 ET | 200 | 2.919 |
01:44 ET | 12263 | 2.94 |
01:46 ET | 642 | 2.94 |
01:48 ET | 200 | 2.94 |
01:50 ET | 3826 | 2.95 |
01:51 ET | 21073 | 2.97 |
01:53 ET | 600 | 2.97 |
01:55 ET | 5750 | 2.965 |
01:57 ET | 1336 | 2.97 |
02:00 ET | 18649 | 2.975 |
02:02 ET | 1626 | 2.98 |
02:04 ET | 3300 | 2.98 |
02:06 ET | 1700 | 2.98 |
02:08 ET | 600 | 2.98 |
02:09 ET | 4319 | 2.98 |
02:11 ET | 1550 | 2.98 |
02:13 ET | 1004 | 2.98 |
02:15 ET | 1889 | 2.98 |
02:18 ET | 7189 | 2.965 |
02:20 ET | 100 | 2.965 |
02:22 ET | 816 | 2.9699 |
02:24 ET | 600 | 2.965 |
02:26 ET | 500 | 2.965 |
02:27 ET | 773 | 2.97 |
02:29 ET | 2448 | 2.97 |
02:31 ET | 500 | 2.97 |
02:33 ET | 5053 | 2.965 |
02:36 ET | 537 | 2.97 |
02:38 ET | 600 | 2.965 |
02:40 ET | 700 | 2.965 |
02:42 ET | 2886 | 2.965 |
02:44 ET | 8968 | 2.955 |
02:45 ET | 800 | 2.955 |
02:47 ET | 100 | 2.96 |
02:49 ET | 200 | 2.95 |
02:54 ET | 600 | 2.95 |
02:56 ET | 1839 | 2.96 |
02:58 ET | 500 | 2.96 |
03:00 ET | 5861 | 2.97 |
03:02 ET | 1600 | 2.97 |
03:03 ET | 700 | 2.97 |
03:05 ET | 700 | 2.965 |
03:07 ET | 1400 | 2.97 |
03:09 ET | 6649 | 2.98 |
03:12 ET | 3585 | 2.99 |
03:14 ET | 2850 | 2.99 |
03:16 ET | 1138 | 2.99 |
03:18 ET | 2482 | 2.99 |
03:20 ET | 7368 | 2.995 |
03:21 ET | 2290 | 2.995 |
03:23 ET | 20291 | 2.985 |
03:25 ET | 100 | 2.99 |
03:27 ET | 700 | 2.985 |
03:30 ET | 972 | 2.985 |
03:32 ET | 400 | 2.985 |
03:34 ET | 1805 | 2.985 |
03:36 ET | 5502 | 2.99 |
03:38 ET | 3024 | 2.99 |
03:39 ET | 2388 | 2.98 |
03:41 ET | 6694 | 2.995 |
03:43 ET | 1200 | 3 |
03:45 ET | 3542 | 3 |
03:48 ET | 1504 | 3 |
03:50 ET | 60054 | 2.985 |
03:52 ET | 4162 | 2.995 |
03:54 ET | 5736 | 3 |
03:56 ET | 24411 | 3.01 |
03:57 ET | 23568 | 3.0099 |
03:59 ET | 99767 | 3.03 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Nuvation Bio Inc | 748.9M | -9.6x | --- |
Perspective Therapeutics Inc | 722.3M | -6.6x | --- |
89Bio Inc | 739.8M | -3.7x | --- |
Savara Inc | 728.4M | -11.5x | --- |
CARGO Therapeutics Inc | 704.7M | -5.3x | --- |
Hillevax Inc | 699.1M | -4.3x | --- |
Nuvation Bio Inc. is a biopharmaceutical company. The Company is engaged in tackling the unmet needs in oncology by developing differentiated and therapeutic candidates. The Company is advancing multiple clinical-stage candidates, including a ROS1 inhibitor, a mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor, a bromodomain and extra-terminal (BET) inhibitor, and a drug-drug conjugate (DDC). Its portfolio of development candidates includes taletrectinib (ROS1), safusidenib (mIDH1), NUV-868 (BET), and NUV-1511 (DDC). Taletrectinib is an oral, potent, CNS-active, selective, ROS1 inhibitor specifically designed for the potential treatment of ROS1-positive non-small cell lung cancer (NSCLC). Safusidenib is an oral, potent, targeted inhibitor of mIDH1 being evaluated in a global Phase II trial in patients with low-grade IDH1-mutant glioma. NUV-868 is a BD2-selective oral small molecule BET inhibitor, that inhibits BRD4. It is conducting Phase I/II study of NUV-1511.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $748.9M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 247.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.40 |
EPS | $-0.31 |
Book Value | $2.76 |
P/E Ratio | -9.6x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.